Key Points
- Use the highest‑yield diagnostic test early; do not let testing delay time‑critical therapy.
- Set objective targets (hemodynamic, neurologic, respiratory) and reassess frequently.
- Plan definitive source control or immunomodulation when indicated; document follow‑up and patient education.
Algorithm
- Activate PPH protocol; uterine massage and assess 4 Ts (Tone, Trauma, Tissue, Thrombin).
- Start oxytocin; establish large‑bore access; send labs and crossmatch.
- Give tranexamic acid 1 g IV within 3 h of birth; repeat once if bleeding persists.
- Escalate uterotonics (methylergonovine → carboprost → misoprostol) as indicated.
- If refractory → intrauterine balloon tamponade; prepare MTP; consider uterine artery embolization or surgical approaches (B‑Lynch, hysterectomy).
Clinical Synopsis & Reasoning
PPH is blood loss ≥1000 mL or bleeding with signs of hypovolemia within 24 h of birth. Manage with uterine massage, first‑line uterotonics, early tranexamic acid, and stepwise escalation to balloon tamponade and surgical interventions with massive transfusion protocols.
Treatment Strategy & Disposition
Stabilize ABCs. Initiate guideline‑concordant first‑line therapy with precise dosing and continuous monitoring. Escalate to advanced or procedural interventions based on explicit failure criteria. Define ICU, step‑down, and ward disposition triggers; involve specialty teams early.
Epidemiology / Risk Factors
- Risk varies by comorbidity and precipitants; see citations for condition‑specific data.
Investigations
| Test | Role / Rationale | Typical Findings | Notes |
|---|---|---|---|
| Quantitative blood loss & vitals | Severity | ≥1000 mL or instability | QBL preferred over EBL |
| Type & cross, coagulation panel, fibrinogen | Transfusion planning | Low fibrinogen predicts severity | Goal‑directed MTP |
| Ultrasound (retained products) | Etiology | Intrauterine contents | Guide management |
Pharmacology
| Medication/Intervention | Mechanism | Onset | Role in Therapy | Limitations |
|---|---|---|---|---|
| Oxytocin 10–40 U in 1 L, IV infusion | Uterotonic | Minutes | First‑line | Hypotension with bolus |
| Tranexamic acid 1 g IV within 3 h (repeat 1 g if bleeding continues) | Antifibrinolytic | Minutes | Reduces mortality (WOMAN trial) | Avoid if active thrombosis |
| Methylergonovine 0.2 mg IM | Uterotonic | Minutes | Second‑line | Avoid in hypertension |
| Carboprost 250 µg IM q15–90 min (max 2 mg) | Uterotonic | Minutes | Third‑line | Avoid in asthma |
| Misoprostol 800–1000 µg PR/SL | Prostaglandin | Minutes | Adjunct | Fever, shivering |
Prognosis / Complications
- Outcome depends on timeliness of diagnosis and definitive therapy; monitor for complications.
Patient Education / Counseling
- Provide red‑flag education, adherence guidance, and explicit return precautions; arrange timely specialty follow‑up.